In previous studies, CD8+ T cells were considered to be the crucial effector cells mediating effective antitumor immunity, resulting in better clinical outcomes, whereas intra-tumoral CD4+ T cells have negative prognostic effects on breast cancer patient outcomes [43]. This evidence concerns the gene CD8A and breast carcinoma.